Rheumatology – Page 3

Distinct Pustular Psoriasis Flares After Biologic Withdrawal in Plaque Psoriasis: Clinical Features and Risk Factors

By MedXY 10/02/2026

This multicenter study identifies a unique pustular psoriasis flare phenotype occurring after biologic therapy withdrawal in plaque psoriasis, detailing clinical characteristics and independent risk factors to guide vigilant monitoring and treatment strategies.

Clinical Updates news Rheumatology

Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior Studies

By MedXY 09/22/2026

Dapirolizumab pegol, a CD40 ligand inhibitor, significantly improves disease activity in moderate-to-severe SLE over 48 weeks when added to standard care, supported by robust phase 3 trial data and pharmacokinetic findings.

Hematology-Oncology news Rheumatology

Unraveling Neutrophil-Driven Interferonopathy in Hemophilic Arthropathy: A New Therapeutic Target

By MedXY 09/20/2026

This study identifies neutrophil-dependent type-I interferon responses and NETs as key drivers of joint damage in hemophilia A, opening avenues for novel therapies to prevent hemophilic arthropathy.

Diabetes & Endocrinology news Rheumatology

Comparing Calorie-Restricted DASH, Carbohydrate-Restricted, and Low-Purine Diets for Weight Loss and Serum Urate Control in Men with Hyperuricemia

By MedXY 09/17/2026

A 12-week randomized trial compared the effects of calorie-restricted DASH, carbohydrate-restricted, and low-purine diets on weight loss and serum urate levels in men with overweight or obesity and hyperuricemia, highlighting adherence and gout flare risks.

Neurology news Rheumatology

IVIG Plus Prednisone Enhances Recovery in Newly Diagnosed Idiopathic Inflammatory Myopathies: Insights from a Randomized Clinical Trial

By MedXY 09/16/2026

A recent randomized trial shows that adding intravenous immunoglobulin (IVIG) to high-dose prednisone significantly improves muscle strength and disease activity in newly diagnosed idiopathic inflammatory myopathies with rapid and clinically meaningful benefits.

Cardiology news Rheumatology

Tocilizumab Reduces Major Cardiovascular Events Risk in Giant Cell Arteritis: Insights from a Nationwide French Cohort

By MedXY 09/08/2026

A nationwide observational study reveals tocilizumab use in giant cell arteritis significantly lowers major adverse cardiovascular events compared to methotrexate, highlighting its potential cardiovascular benefits beyond inflammation control.

news Rheumatology

Targeting TYK2 with Deucravacitinib: Pharmacodynamic Insights from the Phase 2 PAISLEY Trial in Systemic Lupus Erythematosus

By MedXY 09/04/2026

Deucravacitinib, an oral selective TYK2 inhibitor, demonstrates significant suppression of interferon and B-cell pathway biomarkers in active SLE patients, supporting ongoing phase 3 trials for this challenging autoimmune disease.

news Rheumatology

Parenteral vs Oral Glucocorticoids in Early Rheumatoid Arthritis: Impact on Steroid Discontinuation and Therapy Escalation at One Year

By MedXY 09/04/2026

This study assesses whether the administration route of glucocorticoids in early rheumatoid arthritis influences continued steroid use and advanced therapy initiation at one year.

news Otorhinolaryngology Rheumatology

Exploring Janus Kinase Inhibition as a Novel Therapeutic Avenue in Idiopathic Subglottic Stenosis

By MedXY 08/28/2026

JAK inhibitors, proven in rheumatoid arthritis, show potential in extending surgical-free intervals and reducing dilation frequency in idiopathic subglottic stenosis by targeting immune-mediated fibroinflammation.

Gastroenterology news Rheumatology

Decoding Systemic Inflammation in Long COVID and Autoimmune Diseases: The Role of Intestinal Flagellin and the TLR5-IL-15-ARA Axis

By MedXY 08/22/2026

This article explores how intestinal flagellin drives systemic inflammation via the TLR5-IL-15-ARA pathway in long COVID, rheumatoid arthritis, ankylosing spondylitis, and IBD, highlighting potential therapeutic targets and biomarkers.

Gastroenterology news Rheumatology

Unraveling the Gut-Lung Axis: Intestinal Flagellin as a Driver of Multisystem Inflammation via the TLR5-IL-15-ARA Pathway

By MedXY 08/21/2026

Flagellated gut bacteria activate TLR5 on neutrophils, triggering IL-15 release and macrophage arachidonic acid production, driving systemic inflammation in long COVID, rheumatoid arthritis, ankylosing spondylitis, and IBD.

$Early B-Cell Depletion Patterns Predict Long-Term Rituximab Outcomes and Refractory Disease in Rheumatoid Arthritis$

news Rheumatology

Early B-Cell Depletion Patterns Predict Long-Term Rituximab Outcomes and Refractory Disease in Rheumatoid Arthritis

By MedXY 08/20/2026

High-sensitivity flow cytometry reveals that early plasmablast depletion predicts 5-year rituximab response in rheumatoid arthritis, while incomplete memory B-cell depletion signals poly-refractory disease.

news Respiratory Rheumatology

Lung Transplantation in Rheumatoid Arthritis-Associated Interstitial Lung Disease: Identifying Risk Factors and Survival Outcomes in a Universal Healthcare Context

By MedXY 08/17/2026

This study examines lung transplantation patterns, associated risk factors, and post-transplant survival among rheumatoid arthritis-related interstitial lung disease patients in Ontario, revealing key clinical insights under a universal healthcare system.

Nephrology news Rheumatology

Decoding Fibrosis in Lupus Nephritis: Distinct Macrophage-Fibroblast Interactions Fuel Renal Damage

By MedXY 08/17/2026

Spatially distinct macrophage subsets interact with heterogeneous myofibroblast populations in lupus nephritis, driving maladaptive fibrosis and chronic kidney injury. Identifying these fibroinflammatory circuits offers promising targets for therapy to prevent renal decline.

Hematology-Oncology news Rheumatology

Low-dose Blinatumomab Therapy in Multidrug-Resistant Rheumatoid Arthritis: A Case Series Analysis

By MedXY 08/16/2026

A case series assessing the safety and efficacy of low-dose blinatumomab in 15 patients with multidrug-resistant rheumatoid arthritis showed synovial B-cell depletion, reduced disease activity, and improved response to previously ineffective DMARDs.

Clinical Updates Neurology news Rheumatology

Serum Glial Fibrillary Acidic Protein Dynamics in Multiple Sclerosis: Biomarker Insights into Disease Progression and Therapeutic Response

By MedXY 08/04/2026

Serum GFAP elevation predicts progression independent of relapse in MS; therapy-induced GFAP reduction associates with decreased progression risk, supporting GFAP as a biomarker for progression risk stratification and treatment monitoring.

Neurology news Rheumatology

Assessing the Risk of CNS Demyelination Associated with TNF-α Inhibitors: Insights from a Large US Health Network

By MedXY 07/20/2026

A large retrospective study reveals a small but significant increase in CNS demyelination risk among patients treated with TNF-α inhibitors, varying by agent, with generally low absolute incidence.

news Ophthalmology Rheumatology

Comparing Long-Term Systemic Risks of Biologic Versus Conventional Therapy in Non-Infectious Uveitis

By MedXY 07/11/2026

A multicenter retrospective study evaluates five-year risks of systemic complications in non-infectious uveitis patients receiving biologic versus conventional therapies, highlighting infection and cytopenia risks with biologics but comparable overall safety to conventional immunomodulators.

Neurology news Rheumatology

Unraveling the Genetic Basis of Spontaneous Spinal CSF Leaks: Insights from Rare Variant Sequencing and Functional Models

By MedXY 07/01/2026

Rare deleterious variants in FBN2 gene contribute to spontaneous spinal CSF leaks, expanding our understanding of connective tissue involvement and opening paths for genetic testing and tailored therapies.

news Ophthalmology Rheumatology

Ocular Inflammation Linked to Higher Risk of Anti-Adalimumab Antibodies in Autoimmune Disease Patients

By MedXY 05/29/2026

Ocular inflammation was linked to a higher risk of anti-adalimumab antibody formation in patients treated with adalimumab. More than 20% developed antibodies, supporting closer monitoring and therapeutic drug testing in high-risk patients.